San Diego, CA — Binding Site’s Immunologicals Group is pleased to announce the addition of three new recombinant Treponema pallidum antigens to its broad offering of products for in-vitro diagnostic (IVD) manufacturing and research applications. The recombinant T. pallidum TpN-15, TpN-17, and TpN-47 antigens have all been expressly designed for use as an integral component within solid phase enzyme immunoassay test procedures, especially ELISAs. As such, the availability of these antigens will benefit the needs of biopharmaceutical, clinical, and life science researchers, as well as manufacturers of IVD test kits. Treponema pallidum is a spirochete bacterium, with four known subspecies, responsible for treponemal diseases in humans, with Syphilis being the most notable.
The antigens are derived and sourced from E. coli, via culture, which is then purified to a level of >95% and confirmed via SDS PAGE. In addition, all of these recombinant T. pallidum antigens are supplied preservative-free, demonstrate exceptional lot-to-lot consistencies, and feature an outstanding shelf life stability claim of four years from the date of manufacture. The antigens are available in a standard 0.2mg fill-sized vial, with larger, bulk configurations also available.
Binding Site’s Immunologicals Group serves the in-vitro diagnostic (IVD) manufacturing and biopharmaceutical | clinical | life-science | medical research markets with a comprehensive line of innovative products. For additional information, contact The Binding Site, Inc. at 6730 Mesa Ridge Road, San Diego, CA 92121 USA. Phone: 800-633-4484; FAX: 858-453-9189; Email: email@example.com. Please visit our website at www.immunologicals.com.